Singapore Attracts Pharmaceutical Manufacturing Investment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Singapore Attracts Pharmaceutical Manufacturing Investment
Singapore moves forward with a plan to diversify its life science investment with projects in biologics and drug discovery.


Pharmaceutical Technology
Volume 32, Issue 1

Pharmaceutical and biopharmaceutical manufacturing and research and development represent an important part of Singapore's economic base. Several major projects were announced in 2007 as Singapore, along with Ireland and Puerto Rico, compete for investment in the life sciences.

Pharmaceutical manufacturing output

The biomedical sciences (BMS) sector in Singapore is a growing part of the country's economy and is the target of government initiatives to attract investment. "Today, Singapore's BMS industry contributes to slightly over 6% of Singapore's gross domestic product," says Keat-Chuan Yeoh, executive director of the Biomedical Science Board at the Singapore Economic Development Board (EDB), the government agency charged with business development. "In 2006, the BMS industry did extremely well. The manufacturing output grew strongly to S$23 billion (US $16 billion), an unprecedented 30% increase over 2005. The manufacturing output has grown almost fourfold from the year 2000, when we launched the BMS initiative."

In breaking down the BMS sector in 2006, of the total S$23 billion (US $16 billion) in manufacturing output, nearly S$21 billion (US$14.6 billion) was for pharmaceuticals and the balance was for medical technology. Manufacturing data for 2007 is scheduled for release in early 2008.

The BMS initiative was launched in 2000 to establish this sector as the fourth part of Singapore's industry cluster, alongside electronics, chemicals, and engineering, explains Yeoh. "This development was a natural extension of Singapore's capabilities in chemicals and electronics manufacturing," he says.

Key projects in 2007

In 2007, several major projects were announced according to the Singapore EDB in pharmaceutical manufacturing and R&D. These included:

  • A US$700-million cell-culture facility to be built by Novartis (Basel, Switzerland) that will support clinical and commercial production of new biopharmaceuticals, primarily monoclonal antibodies, scheduled for operation in 2012
  • Lonza's (Basel, Switzerland) breaking ground for its second commercial-scale mammalian cell-culture manufacturing plant in Singapore, representing an investment of US$350-million depending upon uptake.
  • Merck & Co.'s (Whitehouse Station, NJ) opening of its regional headquarters in Singapore
  • Genentech's (South San Francisco, CA) decision to set up Singapore's first microbial-based biopharmaceutical manufacturing facility, representing an investment of approximately US$140 million
  • Eli Lilly's (Indianapolis, IN) US$150-million expansion in drug-discovery for the new Lilly-Singapore Center for Drug Discovery
  • GlaxoSmithKline's (London) investment of S$20 million (US$14 million) in its Center for Research in Cognitive and Neurodegenerative Disorders for the construction of two medicinal chemistry laboratories
  • Eisai's regional clinical coordination and management center in Singapore.

Key projects in 2006

These investments follow several major projects in 2006 as identified by the Singapore EDB. These projects include:

  • GlaxoSmithKline's S$300-million (US$210-million) vaccine manufacturing plant in Singapore, which is scheduled to be operational in 2010
  • Merck & Co.'s S$100-million (US$ 70 million) expansion of formulation-manufacturing facilities and supporting infrastructure
  • Lonza's breaking ground for its first large-scale mammalian cell-culture manufacturing plant representing a US$250-million investment
  • Novartis's creation of a new malaria research program in partnership with Wellcome Trust, Medicines for Malaria Venture, and the Singapore EBD
  • Abbott Laboratories' (Abbott Park, IL) US$280-million nutritional powder manufacturing plant
  • Covance's (Princeton, NJ) opening of an expanded central laboratory to support biopharmaceutical clients in global clinical trials
  • SGS's (Geneva, Switzerland) opening of its new laboratory for quality control testing in analytical chemistry, microbiological testing, method development and validation, and stability testing
  • The biopharmaceutical company PT Kalbe Farma's (Banten, Indonesia) opening offices for research and coordination licensing in Singapore.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here